APRE (Aprea Therapeutics, Inc. Common stock)
Insider Trading Activity
Every open-market purchase and sale reported by APRE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Marc Duey | Director | A | — | — |
| 2026-06-17 | Richard Peters | Director | A | — | — |
| 2026-06-17 | Bernd R. Seizinger | Director | A | — | — |
| 2026-06-17 | Michael Grissinger | Director | A | — | — |
| 2026-06-17 | Gabriela Gruia | Director | A | — | — |
| 2026-06-17 | Rifat Pamukcu | Director | A | — | — |
| 2026-06-17 | JOHN B HENNEMAN III | Director | A | — | — |
| 2026-06-17 | JEAN-PIERRE BIZZARI | Director | A | — | — |
| 2026-04-01 | Richard Peters | Director | Buy | — | — |
| 2026-04-01 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | — | — |
| 2026-03-16 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | A | — | — |
| 2026-03-16 | Oren Gilad | President/CEO | A | — | — |
| 2026-02-02 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | — | — |
| 2026-02-02 | Oren Gilad | President/CEO | Buy | — | — |
| 2025-12-11 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | — | — |
| 2025-12-11 | Oren Gilad | President/CEO | Buy | — | — |
| 2025-12-11 | Marc Duey | Director | Buy | — | — |
| 2025-06-09 | Michael Grissinger | Director | A | — | — |
| 2025-06-09 | Bernd R. Seizinger | Director | A | — | — |
| 2025-06-09 | Gabriela Gruia | Director | A | — | — |
| 2025-06-09 | JEAN-PIERRE BIZZARI | Director | A | — | — |
| 2025-06-09 | Marc Duey | Director | A | — | — |
| 2025-06-09 | JOHN B HENNEMAN III | Director | A | — | — |
| 2025-06-09 | Richard Peters | Director | A | — | — |
| 2025-06-09 | Rifat Pamukcu | Director | A | — | — |
| 2025-04-04 | Oren Gilad | President/CEO | Buy | — | — |
| 2025-03-31 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | A | — | — |
| 2025-03-31 | Oren Gilad | President/CEO | A | — | — |
| 2024-10-25 | Marc Duey | Director | Sell | — | — |
| 2024-10-24 | Oren Gilad | President/CEO | Buy | — | — |
| 2024-10-17 | Marc Duey | Director | Buy | — | — |
| 2024-10-16 | Marc Duey | Director | Buy | — | — |
| 2024-10-16 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | — | — |
| 2024-10-16 | Oren Gilad | President/CEO | Buy | — | — |
| 2024-10-15 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | — | — |
| 2024-10-15 | Bernd R. Seizinger | Director | Buy | — | — |
| 2024-10-15 | Oren Gilad | President/CEO | Buy | — | — |
| 2024-06-21 | Richard Peters | Director | A | — | — |
| 2024-06-21 | Marc Duey | Director | A | — | — |
| 2024-06-21 | JOHN B HENNEMAN III | Director | A | — | — |
| 2024-06-21 | Michael Grissinger | Director | A | — | — |
| 2024-06-21 | Bernd R. Seizinger | Director | A | — | — |
| 2024-06-21 | Rifat Pamukcu | Director | A | — | — |
| 2024-05-02 | Nadeem Q. Mirza | Chief Medical Officer | A | — | — |
| 2024-03-28 | Oren Gilad | President, CEO | A | — | — |
| 2024-03-28 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | A | — | — |
| 2024-03-14 | Oren Gilad | President, CEO | Buy | — | — |
| 2024-03-14 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | — | — |
| 2024-03-14 | JOHN B HENNEMAN III | Director | Buy | — | — |
| 2024-03-14 | Bernd R. Seizinger | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President/CEO | 395,095 | — |
| — | Director | 259,892 | — |
| — | 10%+ Owner | 142,633 | — |
| — | 10%+ Owner | 142,633 | — |
| — | Director | 118,305 | — |
| — | 10%+ Owner | 99,629 | — |
| — | 10%+ Owner | 96,927 | — |
| — | 10%+ Owner | 96,304 | — |
| — | 10%+ Owner | 93,436 | — |
| — | 10%+ Owner | 88,436 | — |
| — | 10%+ Owner | 83,597 | — |
| — | Director | 48,910 | — |
| — | SrVP/CFO/Prin Fin & Acct Ofcr | 43,528 | — |
| — | Director | 22,689 | — |
| — | 10%+ Owner | 16,667 | — |
| — | Director | 13,364 | — |
| — | Chairman & CEO | 13,212 | — |
| — | 10%+ Owner | 10,833 | — |
| — | SVP, Chief Financial Officer | 7,253 | — |
| — | Chief Medical Officer | 6,730 | — |
| — | Director | 6,254 | — |
| — | Director | 6,024 | — |
| — | Director | 4,180 | — |
| — | Director | 4,180 | — |
| — | — | 3,798 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APRE quote page; the site-wide leaderboard is on the insider transactions hub.